High Dose Cyclophosphamide Plus Recombinant Human Granulocyte-colony Stimulating Factor (rhG-CSF) in the Treatment of Follicular, Low Grade Non-Hodgkin's Lymphoma: CALGB 9150

This publication has 21 references indexed in Scilit:

• Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy
  Journal of Clinical Oncology, 1999
• Treatment of follicular lymphoma
  Current Opinion in Oncology, 1998
• Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
  Journal of Clinical Oncology, 1998
• 2-Chlorodeoxyadenosine as Initial Therapy for Advanced Low Grade Lymphomas
  Leukemia & Lymphoma, 1997
• A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
  New England Journal of Medicine, 1993
• Phase I Trial of Granulocyte--Macrophage Colony-Stimulating Factor Plus High-Dose Cyclophosphamide Given Every 2 Weeks: a Cancer and Leukemia Group B Study
  JNCI Journal of the National Cancer Institute, 1993
• Immunologic Purging of Marrow Assessed by PCR before Autologous Bone Marrow Transplantation for B-Cell Lymphoma
  New England Journal of Medicine, 1991
• Mechanism of the t(14;18) chromosomal translocation: structural analysis of both derivative 14 and 18 reciprocal partners.
  Proceedings of the National Academy of Sciences, 1987
• Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type.
  BMJ, 1978
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958